Worldwide HealthcareWWH:LSE

1,571
0.00 / 0.00%
24.58k
32.02%
0.5623
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Oct 30 2014 12:40 GMT.

Total returns on £1000

Fund / BenchmarkChange
PriceWorldwide Healthcare (Ordinary Share)+29.35%
Worldwide Healthcare (Ordinary Share)+31.57%
Morningstar's BenchmarkFTSE World+4.90%
As of Oct 27 2014.

Worldwide Healthcare summary

Shares outstanding47.87m
Market cap752.00m GBP
Total assets850.10m GBP
Total expense ratio1.01%
Day high1,580
Day low1,565
Previous close1,571
Average volume62.41k
YTD Change+26.80 %
Beta0.5623%
Diluted NAV (est)1,618.75
Diluted NAV (last pub)1,626.06
Premium/Discount-2.95 %
Gearing+110.00 %
52-week range
Today
1,179
Nov 13 2013
1,580
Oct 29 2014

WWH:LSE set a new 52-week high during Wednesday's trading session when it reached 1,580. Over this period, the share price is up 32.57%.

Data delayed at least 15 minutes, as of Oct 30 2014 12:40 GMT.

Profile

Management group(s)OrbiMed Capital LLC
AIC sectorSector Specialist: Biotechnology/Life Sciences
ISINGB0003385308
Launch date28 Apr 1995
Share typeOrdinary Share
StructureConventional
Base currencyGBP

Objective

To invest worldwide in pharmaceutical and biotechnology companies with the aim of achieving a high level of capital growth.

Management & contract fees

The Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The performance fee amounts to 16.5% of any out-performance of the NAV over the benchmark index.

Dividend

Div yield1.0609
Div ex-date04 Jun 2014
Div pay-date04 Jul 2014

Managed by

Sven Borho Start : 01 Feb 2013
Samuel. D Isaly Start : 28 Apr 1995
Data delayed at least 15 minutes, as of Oct 30 2014 12:40 GMT.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.